AIM ImmunoTech (AIM) Competitors $0.21 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends AIM vs. PRLD, KRON, VIRI, CUE, JATT, DTIL, ITRM, STTK, TARA, and ACABShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Prelude Therapeutics (PRLD), Kronos Bio (KRON), Virios Therapeutics (VIRI), Cue Biopharma (CUE), JATT Acquisition (JATT), Precision BioSciences (DTIL), Iterum Therapeutics (ITRM), Shattuck Labs (STTK), Protara Therapeutics (TARA), and Atlantic Coastal Acquisition Corp. II (ACAB). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Prelude Therapeutics Kronos Bio Virios Therapeutics Cue Biopharma JATT Acquisition Precision BioSciences Iterum Therapeutics Shattuck Labs Protara Therapeutics Atlantic Coastal Acquisition Corp. II Prelude Therapeutics (NASDAQ:PRLD) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking. Does the MarketBeat Community favor PRLD or AIM? AIM ImmunoTech received 29 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 82.86% of users gave AIM ImmunoTech an outperform vote while only 48.33% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes2948.33% Underperform Votes3151.67% AIM ImmunoTechOutperform Votes5882.86% Underperform Votes1217.14% Which has more risk and volatility, PRLD or AIM? Prelude Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, suggesting that its share price is 136% less volatile than the S&P 500. Is PRLD or AIM more profitable? Prelude Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Prelude Therapeutics' return on equity of -66.89% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% AIM ImmunoTech -12,594.21%-421.73%-147.54% Does the media prefer PRLD or AIM? In the previous week, AIM ImmunoTech had 8 more articles in the media than Prelude Therapeutics. MarketBeat recorded 9 mentions for AIM ImmunoTech and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.95 beat AIM ImmunoTech's score of 0.70 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AIM ImmunoTech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in PRLD or AIM? 79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 62.8% of Prelude Therapeutics shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, PRLD or AIM? AIM ImmunoTech has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude TherapeuticsN/AN/A-$121.83M-$1.78-0.53AIM ImmunoTech$190K70.45-$28.96M-$0.47-0.45 Do analysts recommend PRLD or AIM? Prelude Therapeutics currently has a consensus target price of $4.75, indicating a potential upside of 400.69%. AIM ImmunoTech has a consensus target price of $3.00, indicating a potential upside of 1,327.89%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAIM ImmunoTech beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$13.39M$3.04B$5.38B$20.14BDividend YieldN/A1.91%5.13%3.50%P/E Ratio-0.4545.50105.1444.57Price / Sales70.45392.401,233.1517.74Price / CashN/A169.3840.4121.28Price / Book4.204.597.094.71Net Income-$28.96M-$41.63M$119.65M$986.85M7 Day Performance-5.78%2.61%2.25%3.76%1 Month Performance-19.16%-2.47%-2.33%4.65%1 Year Performance-50.56%28.24%33.98%27.72% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.9963 of 5 stars$0.21flat$3.00+1,327.9%-50.6%$13.39M$190,000.00-0.4520News CoveragePRLDPrelude Therapeutics3.0003 of 5 stars$0.97+1.0%$4.75+391.1%-71.8%$53.23MN/A-0.54120Positive NewsKRONKronos Bio3.4608 of 5 stars$0.87+1.2%$1.63+85.9%-27.2%$52.76M$6.29M-0.61100Gap UpVIRIVirios Therapeutics0.7303 of 5 stars$2.71+11.5%$3.00+10.7%+303.7%$52.19MN/A-10.045Gap DownCUECue Biopharma4.4711 of 5 stars$1.03-5.5%$5.00+385.4%-57.3%$50.10M$5.49M-1.2160JATTJATT AcquisitionN/A$2.90-7.9%N/A-34.3%$50.03MN/A0.003High Trading VolumeDTILPrecision BioSciences4.043 of 5 stars$6.50-9.5%$39.50+507.7%-42.9%$49.86M$48.73M109.02200High Trading VolumeITRMIterum Therapeutics1.5332 of 5 stars$1.78+9.2%$5.00+181.7%-12.6%$48.85MN/A-0.8910STTKShattuck Labs2.6483 of 5 stars$1.01-9.0%$8.67+758.1%-56.9%$48.22M$1.66M-0.66100TARAProtara Therapeutics1.9633 of 5 stars$2.29-0.9%$24.00+948.0%+117.3%$47.24MN/A0.0030ACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.6%$47.14MN/A0.004High Trading Volume Related Companies and Tools Related Companies PRLD Alternatives KRON Alternatives VIRI Alternatives CUE Alternatives JATT Alternatives DTIL Alternatives ITRM Alternatives STTK Alternatives TARA Alternatives ACAB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:AIM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
